Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Novo Nordisk's surprise bid for Metsera has set the stage for a high-stakes showdown in the obesity drug market, with Pfizer ...

Analysts say Pfizer could use its strong connections within the Trump administration to bolster its case, with CEO Albert ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Explore the fierce competition between Novo Nordisk and Pfizer as they vie for Metsera amidst a booming obesity drug market.

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential ...

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...

Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding ...

Novo Nordisk recently confirmed reports about its unsolicited proposal submission to Metsera, aimed at acquiring its early ...